ALMS

Business Context and Reporting Period

Company: Alumis Inc. (ALMS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune disorders, specifically Tyrosine Kinase 2 (TYK2) inhibitors. Its lead product candidate, ESK-001, is in Phase 2 trials for psoriasis and systemic lupus erythematosus (SLE). A second candidate, A-005, is in Phase 1 for neuroinflammatory diseases.
Corporate Status: As of the filing date, the company was pre-IPO. The Initial Public Offering (IPO) and a Concurrent Private Placement closed in July 2024, subsequent to the reporting period.

Key Financial Metrics

Note: The company has no revenue and operates at a loss. The balance sheet reflects the pre-IPO capital structure with significant redeemable convertible preferred stock.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 56% for the three months ended June 30, 2024, compared to the same period in 2023 ($56.5M vs. $36.3M). For the six months, the loss increased by 47% ($106.4M vs. $72.3M).
• Operating Expenses: Total operating expenses rose 49% quarter-over-quarter and 40% year-to-date.
  • R&D Expenses: Increased 48% (QoQ) and 39% (YTD) to $48.6M and $90.5M, respectively. This was driven by higher costs for CRO/CMO services and clinical trials for ESK-001 and A-005, as well as increased personnel costs.
  • G&A Expenses: Increased 59% (QoQ) and 47% (YTD) to $7.6M and $13.2M, respectively, due to increased headcount and professional services.
• Derivative Liability: The company recognized a loss of $2.3M (QoQ) and $5.4M (YTD) related to the change in fair value of a derivative liability associated with Series C preferred stock financing, compared to a gain of $0.4M in the prior year periods.
• Liquidity Position: Cash and cash equivalents increased significantly from $46.0M at December 31, 2023, to $155.1M at June 30, 2024, primarily due to the issuance of Series C preferred stock.

Guidance, Outlook, and Risks

• Subsequent Events (IPO): On July 1, 2024, the company completed its IPO, selling 13.125 million shares at $16.00 per share, raising approximately $193.2 million in net proceeds. A concurrent private placement raised an additional $40.0 million. All preferred stock converted to common stock immediately prior to the IPO.
• Liquidity Outlook: Management believes that existing cash ($209.5M as of June 30) plus IPO proceeds ($233.2M) will fund operations for at least the next 12 months.
• Clinical Milestones: In July 2024, the company met a milestone for the first administration of ESK-001 in a Phase 3 trial, triggering a $23.0 million contingent payment obligation expected in Q3 2024.
• Key Risks:
  • Development Risk: High uncertainty in clinical trial outcomes; the company discontinued a Phase 2a trial for ESK-001 in non-infectious uveitis in June 2024 due to efficacy results not meeting thresholds.
  • Capital Requirements: The company expects to incur substantial losses for the foreseeable future and will require additional financing to achieve profitability.
  • Regulatory Risk: Dependence on FDA and foreign regulatory approvals, which are lengthy and uncertain.

Investor Verification Checklist

• Post-IPO Capitalization: Verify the final share count and ownership structure following the conversion of preferred stock and the IPO issuance.
• Cash Burn Rate: Assess the sustainability of the $106M six-month net loss against the combined cash balance of ~$443M (pre-IPO cash + IPO proceeds).
• Contingent Liabilities: Confirm the timing and accounting treatment of the $23.0 million milestone payment triggered in July 2024.
• Clinical Pipeline Status: Monitor the progress of the Phase 3 trials for ESK-001 in psoriasis and the Phase 1 trial for A-005, given the recent discontinuation of the uveitis trial.
• Stock-Based Compensation: Review the impact of the new 2024 Equity Incentive Plan and Performance Option Plan on future operating expenses.